Esperion Therapeutics | ESPR - Vertriebs- Und Verwaltungskosten

Aktienkurs
2.64
Täglich Wechseln
0.09 3.33%
Monatlich
-20.15%
Jährlich
51.44%
Q1 Prognose
2.47




Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.89B 325M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Alterity Therapeutics Limited AUD 2.29M 649.1K 2023-06
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Cipla INR 13.25B 101.8M 2025-12
CSL USD 1.23B 498M 2025-12
Cytokinetics USD 91.72M 67.02M 2025-12
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Geron USD 41.67M 2.67M 2025-12
Grifols EUR 320.45M 12.65M 2025-12
Halozyme Therapeutics USD 64.64M 27.11M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Merck USD 2.85B 215M 2025-12
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 308M 40M 2025-12
Nektar Therapeutics USD -0.18 0.07 2024-09
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12